中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

52 records (took 0.018 seconds)

    METHOD OF PRODUCING MEDICAMENTS IN SOLID FORM
    3.
    发明申请
    METHOD OF PRODUCING MEDICAMENTS IN SOLID FORM 审中-公开
    用于固体药物剂型的研制

    公开(公告)号：WO1997015290A1

    公开(公告)日：1997-05-01

    申请号：PCT/EP1996004584

    申请日：1996-10-22

    Applicant: BASF AKTIENGESELLSCHAFT ,  BREITENBACH, Jörg ,  HÄRTL, Axel, Paul ,  ROSENBERG, Joerg ,  SCHIESSL, Michael ,  ZETTLER, Hans, Dieter

    Inventor： BASF AKTIENGESELLSCHAFT

    IPC: A61K09/20

    CPC classification number: A61K9/1694 ,  A61K9/2095

    Abstract: The invention concerns a method of producing medicaments in solid form by mixing at least one pharmacologically acceptable polymer binder, at least one pharmaceutical active substance and optionally conventional pharmaceutical additives, extruding the mixture and shaping the medicament, a pre-mixture being prepared from the components and fed into the extruder. The method according to the invention enables high-quality medicaments to be produced in a simple and careful manner.

    Abstract translation: 本发明涉及一种用于通过混合至少一种药理学上可接受的聚合物粘合剂，至少一种药用活性物质和任选的共同药物添加剂，挤出该混合物和剂型，该方法包括从一个预混合料的成分制备的成形产生的固体剂型，并且这 送入挤出机。 本发明的方法允许简单和温和的生产具有高产品质量的剂型。

    SUSTAINED-RELEASE MATRIX PELLETS AND METHOD FOR PREPARING THEM
    5.
    发明申请
    SUSTAINED-RELEASE MATRIX PELLETS AND METHOD FOR PREPARING THEM 审中-公开
    RETARD-骨架丸和工艺及其

    公开(公告)号：WO1995028147A1

    公开(公告)日：1995-10-26

    申请号：PCT/EP1995001236

    申请日：1995-04-05

    Applicant: BASF AKTIENGESELLSCHAFT ,  GRABOWSKI, Sven ,  ROSENBERG, Joerg ,  SANNER, Axel

    Inventor： BASF AKTIENGESELLSCHAFT

    IPC: A61K09/16

    CPC classification number: A61K9/1652 ,  A61K9/1617 ,  A61K9/1694

    Abstract: Disclosed are sustained-release matrix pellets of spherical to lenticular shape and uniform maximum diameter in the range of 0-5 to 4 mm, consisting of a) 0.1 to 87 wt % of at least one biologically active compound, b) 5 to 50 wt % of at least one water-insoluble polymer, c) 5-45 wt % of at least one lipophilic component as plasticizer for the b) polymer, d) 3 to 40 wt % of a natural or semisynthetic gelling agent, e) 0 to 50 wt% of one or more common formulation auxiliaries.

    Abstract translation: 缓释基质小丸具有球形透镜形状和均匀的在0.5至4mm的范围内的最大直径，包括一）0.1〜87重量％的至少一种生物活性化合物的％，B）5至50重量份 至少一种不溶于水的聚合物，C）5至45重量％的至少一种亲油性组分如增塑剂聚合物b的％）的％，D）3〜40重量天然或半合成的凝胶形成剂，电子的％）0至50重量份 ％的一种或多种常规配制辅剂。

    FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS
    8.
    发明申请
    FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS 审中-公开
    非对称性和限制性阿片类药物的制剂

    公开(公告)号：WO2009014534A1

    公开(公告)日：2009-01-29

    申请号：PCT/US2007/073957

    申请日：2007-07-20

    Applicant: ABBOTT GMBH & CO. KG ,  LIU ,  ROSENBERG, Joerg ,  WOEHRLE, Gerd ,  KESSLER, Thomas Y. ,  BREITENBACH, Joerg ,  DURAK, Salih ,  RICHTER, Friedrich W. ,  DUTTA, Sandeep

    Inventor： ROSENBERG, Joerg ,  WOEHRLE, Gerd ,  KESSLER, Thomas Y. ,  BREITENBACH, Joerg ,  DURAK, Salih ,  RICHTER, Friedrich W. ,  DUTTA, Sandeep

    IPC: A61K9/28 ,  A61K31/00

    CPC classification number: A61K9/284 ,  A61K9/2853 ,  A61K9/2866 ,  A61K31/167 ,  A61K31/485 ,  A61K2300/00

    Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

    Abstract translation: 本申请中优选的示例性实施方案提供用于递送药物，特别是滥用药物，具有基本上限于核心的滥用相关药物和非核心区域中的非滥用相关药物的制剂和方法。 这些制剂减少了滥用的可能性。 在制剂中，优选滥用相关药物是阿片样物质，非滥用相关药物是对乙酰氨基酚或布洛芬。 更优选地，阿片样物质是氢可酮，非滥用相关镇痛药是对乙酰氨基酚。 在某些优选的实施方案中，剂型的特征在于耐溶剂萃取; 篡改，破碎或研磨。 本发明的某些实施方案提供剂型，其提供药物释放的初始爆发，随后延长药物释放时间。

    PRODUCTION OF DOSAGE FORMS COMPRISING A SOLID DISPERSION OF A MICROCRYSTALLINE AGENT
    10.
    发明申请
    PRODUCTION OF DOSAGE FORMS COMPRISING A SOLID DISPERSION OF A MICROCRYSTALLINE AGENT 审中-公开
    剂型的用微结晶活性的固体分散体制造

    公开(公告)号：WO2006084696A9

    公开(公告)日：2007-10-25

    申请号：PCT/EP2006001164

    申请日：2006-02-09

    Applicant: ABBOTT GMBH & CO KG ,  ROSENBERG JOERG ,  MAEGERLEIN MARKUS ,  LIEPOLD BERND ,  BREITENBACH JOERG

    Inventor： ROSENBERG JOERG ,  MAEGERLEIN MARKUS ,  LIEPOLD BERND ,  BREITENBACH JOERG

    IPC: A61K9/14 ,  A61K9/00

    CPC classification number: A61K9/146 ,  A61K9/145

    Abstract: Disclosed is a method for producing dosage forms comprising a solid dispersion of a microcrystalline agent. According to said method, a thermoplastic polymer having a minimum glass transition temperature Tg of 40 o C is melted, and an agent is homogeneously dissolved in the melt; crystallization of the agent is initiated in the obtained mass; and the mass is cooled. Crystallization of the agent can be initiated by adding a nonsolvent, seed crystals of the agent, or a derivatization reagent. Crystallization can also be initiated by maintaining the mass at a certain temperature for a sufficient amount of time, said temperature being lower than the temperature at which the agent can be fully dissolved in the mass.

    Abstract translation: 公开了一种用于剂型，其包含熔化具有至少40℃的玻璃化转变温度Tg℃的热塑性聚合物和触发均匀熔融活性成分的微晶的活性成分的固体分散体的制备方法; 在活性成分的所得到的质量开始结晶; 和物料冷却。 活性成分的结晶，通过添加非溶剂，通过将活性成分或衍生试剂的晶种引发。 另外一个可以通过保持有足够的时间的质量在比在该活性物质是在所述组合物完全可溶于温度低的温度下开始结晶。

Patent Agency Ranking